Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention.

[1]  J. Early,et al.  Producer Price Indexes , 2006 .

[2]  P. Eriksson.  Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the "Emperor's New Clothes" revisited. , 2004, European heart journal.

[3]  S. Yusuf,et al.  Cost‐effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long‐term model based on the cure trial , 2004, Journal of internal medicine.

[4]  C. Gross,et al.  Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study. , 2003, American heart journal.

[5]  V. Hasselblad,et al.  Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. , 2003, The American journal of cardiology.

[6]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[7]  J. W. Schaeffer,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article , 2002 .

[8]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[9]  S. Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study ☆ , 2002 .

[10]  Abdullah Al Mamun,et al.  A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. , 2002, European heart journal.

[11]  Deepak L. Bhatt,et al.  Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. , 2002, Journal of the American College of Cardiology.

[12]  R. Califf,et al.  Economic Assessment of Platelet Glycoprotein IIb/IIIa Receptor Blockade With Abciximab and Low-Dose Heparin During Percutaneous Coronary Revascularization: Results From the EPILOG Randomized Trial , 2000, Circulation.

[13]  A A Tsiatis,et al.  Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. , 2000, Circulation.

[14]  J. Schwartz,et al.  Comparative economic data regarding lipid-lowering drugs , 1999 .

[15]  E. DeLong,et al.  Acute and long-term cost implications of coronary stenting. , 1999, Journal of the American College of Cardiology.

[16]  D. Huse,et al.  Cost-effectiveness of statins. , 1998, The American journal of cardiology.

[17]  M. Weinstein,et al.  Evaluating the cost-effectiveness of clinical and public health measures. , 1998, Annual review of public health.

[18]  A. Kastrati,et al.  A RANDOMIZED COMPARISON OF ANTIPLATELET THERAPY AFTER THE PLACEMENT OF CORONARY ARTERY STENTS , 1996 .

[19]  J. Eisenberg,et al.  Clinical Economics: A Guide to the Economic Analysis of Clinical Practices , 1989 .